Martin Shkreli recently gained widespread opprobrium when his company raised the price of Daraprim, a 62-year-old old drug used to treat Aids patients, by 5,000 per cent to more than $750 a pill.
The pricing strategy by Shkreli’s Turing Pharmaceuticals infuriated the public. Suddenly, pharmaceutical pricing entered the presidential debate in the US.
Billionaire Donald Trump, the Republican presidential frontrunner, called Shkreli a “spoiled brat”, while Democratic frontrunner Hillary Clinton tweeted about it as a...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team